|
1.There was an allegation of questionable elecsys ft3 iii results for 3 patients from cobas e 801 analytical units and 2 patients from cobas 8000 core units.2.Patient age range: asku, 19-69.Years.3.Patient weight range: asku.4.Patient sex breakdown: 2-female, 1-male, 2-asku.5.Patient race breakdown: asku.6.Patient ethnicity breakdown: asku.
|
|
For 1 of the pending events: 1.Summary of investigation results: no interfering factor was detected in the sample during the investigation, and the customer's results could not be reproduced.The issue was consistent with a sample-specific issue or an error at the customer site.For diagnostic purposes, the results should always be assessed in conjunction with the patient´s medical history, clinical examination and other findings.2.Summary of follow-up/corrective actions taken: none for 1 of the pending events: 1.Summary of investigation results: the investigation did not identify a product problem.2.Summary of follow-up/corrective actions taken: the patient's sample was not available for investigation.For 1 of the pending events: 1.Summary of investigation results: the investigation determined that an interferent in the patient sample had caused the event.Product labeling states, "in rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.These effects are minimized by suitable test design.For diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination and other findings." the investigation did not identify a product problem.2.Summary of follow-up/corrective actions taken: the patient sample was tested for interferents.For 1 of the pending events: 1.Summary of investigation results: no interfering factor was detected in the sample during the investigation.Product labeling states: "for diagnostic purposes, the results should always be assessed in conjunction with the patient¿s medical history, clinical examination and other findings." the investigation did not identify a product problem.2.Summary of follow-up/corrective actions taken: the patient sample was tested for interferents.
|